Full-Time

Staff Quality Engineer

Supplier Quality Validation

Integra LifeSciences

Integra LifeSciences

1,001-5,000 employees

Regenerative medicine, surgical devices provider

Compensation Overview

$109.3k - $149.5k/yr

+ Bonus + Commission + Equity

Mansfield, MA, USA + 1 more

More locations: Princeton, NJ, USA

Remote

Travel up to 10% is required, with possible international travel.

Bachelor's, Master's, PhD

Category
QA & Testing (1)
Required Skills
ISO 9001
GMP
Data Analysis

Get referred to Integra LifeSciences

See people who can refer or advise you

Requirements
  • A bachelor's degree or equivalent with 10+ years of experience, a master's degree with 8+ years of experience, or a doctoral degree with 5+ years of experience in manufacturing engineering, mechanical engineering, industrial engineering, quality, or a relevant engineering degree.
  • Fluency in English with strong communication skills.
  • Strong experience in process validation and component qualification, including IQ/OQ/PQ and data analytics.
  • Medical device or pharmaceutical experience.
  • Experience in an FDA- and other regulatory-controlled environment.
  • Strong collaboration skills and experience working in a matrix environment.
  • Ability to read and understand technical and statistical documents.
  • Ability to interface with technical and non-technical personnel.
  • Knowledge of current Good Manufacturing Practices and other applicable standards.
  • Experience using analytical tools to drive data-based decision-making.
Responsibilities
  • Communicate, verify, and execute process validations of supplier processes involving products procured and used by the organization.
  • Ensure supplier process-validation requirements, including critical-to-quality requirements, drawings, specifications, first article inspections, and IQ/OQ/PQ protocols, are communicated, completed, and verified.
  • Drive continuous improvement in supplier-quality processes through data analysis and identification of improvement areas.
  • Perform for-cause audits to determine root cause and drive corrective and preventive actions while supporting site supplier-quality teams.
  • Support sites by leading critical supplier-quality issues, including supplier visits and audits when required.
  • Review and approve executed IQ/OQ/PQ qualification documentation with suppliers for new-product and life-cycle-change-management projects.
  • Develop and promote behaviors that sustain a culture of continuous improvement supporting short- and long-term business objectives.
  • Support the supplier-consolidation initiative.
  • Provide and develop training on process-validation concepts for the team and organization as needed.
  • Use coaching and facilitation skills with program stakeholders to support project management, expectation setting, and best-practice use.
  • Direct GSQ department activities to ensure compliance with applicable regulations and standards, including FDA, ISO 13485, CMDR, MDR, 21 CFR Part 11, and IQ/OQ/PQ.
  • Interact and coordinate activities with other departments, external vendors, and customers.
  • Influence and collaborate across stakeholder groups to identify and implement process and continuous-improvement opportunities.
Desired Qualifications
  • Experience or knowledge of ISO 9001 and ISO 13485 requirements.

Integra LifeSciences develops medical technologies for tissue repair and regeneration, including tissue-regeneration scaffolds, neurosurgical devices, wound care products, and specialized surgical instruments. Its scaffolds are implanted on wounds to provide a temporary matrix that guides new tissue growth and gradually integrates with the patient's tissue. The company differentiates itself through a diversified, multi-domain portfolio built via acquisitions, spanning regenerative medicine and conventional medical devices. Its goal is to broaden access to regenerative technology and raise standards of care in surgery and tissue repair.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Plainsboro Township, New Jersey

Founded

1989

Get referred to Integra LifeSciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 production started at Braintree, supporting a planned Q4 SurgiMend relaunch.
  • Integra reaffirmed 2026 organic growth guidance of 0.8% to 3.3%.
  • Management targets $200 million operating cash flow as supply reliability improves.

What critics are saying

  • FDA's January 2026 MediHoney recall covered all lots after 11 serious injuries.
  • Quality-system failures still threaten SurgiMend and DuraRepair timelines through 2026.
  • Net debt was $1.6 billion in Q1 2026, limiting strategic flexibility.

What makes Integra LifeSciences unique

  • Integra spans neurosurgery, tissue reconstruction, and regenerative wound-care niches.
  • Its Braintree, Massachusetts facility centralizes resumed PriMatrix and SurgiMend manufacturing.
  • Few medtech peers combine biologics, implants, and surgical instruments at this scale.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical Insurance

Dental Insurance

Vision Insurance

Short-Term Disability

Long-Term Disability

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

4%

2 year growth

4%
Yahoo Finance
May 29th, 2026
Integra LifeSciences shares jump 6% after Citigroup upgrades rating and raises price target to $16

Integra LifeSciences shares rose 6.1% after Citigroup upgraded its rating from Sell to Neutral and raised its price target to $16 from $11. Analyst Joanne Wuensch's upgrade reflects reduced downside risk, though not yet a bullish outlook. The upgrade follows strong first-quarter 2026 results reported 22 days earlier, when the stock gained 5.3%. Integra's revenue grew 2.4% year-on-year to $391.9 million, beating estimates, whilst adjusted earnings per share of $0.54 exceeded consensus by 32.8%. The company raised its full-year earnings guidance and appointed Stuart Essig as CEO. Integra shares are up 36.7% year-to-date and recently hit a 52-week high of $16.42, though five-year returns remain significantly negative.

Yahoo Finance
May 17th, 2026
Integra LifeSciences targets $200M operating cash flow as SurgiMend relaunch nears Q4

Integra LifeSciences reported first-quarter revenue and earnings per share above guidance, citing progress in its operational transformation efforts. Chief Financial Officer Lea Knight said internal indicators show fewer supply disruptions, better yields and improved cash flow. The company is maintaining its focus on neurosurgery, tissue reconstruction and ENT markets following a leadership change that saw Stuart return as chairman and CEO. Integra is preparing to relaunch SurgiMend in the fourth quarter after operationalising its Braintree manufacturing facility in June and rebuilding inventory in the third quarter. Management expects $25 million to $30 million in cost savings and is targeting approximately $200 million in operating cash flow and $140 million in free cash flow this year. The company also reported reduced tariff pressure, with full-year impacts now expected at $0.10 per share versus a prior estimate of $0.32.

Yahoo Finance
May 15th, 2026
Integra LifeSciences beats Q1 expectations, raises full-year EPS guidance to $2.45

Integra LifeSciences reported first-quarter results that beat Wall Street expectations, with revenue of $391.9 million and adjusted EPS of $0.54, surpassing estimates by 2.6% and 33.4%, respectively. The medical device company attributed the performance to stronger tissue reconstruction demand, improved supply execution and operational improvements. CEO Stuart Essig emphasised that quality remediation and operational work enabled more reliable product availability. CFO Lea Knight said increased gross margins were driven by favourable product mix, tariff benefits and reduced remediation costs. The company reaffirmed its full-year revenue guidance of $1.68 billion whilst raising adjusted EPS guidance to $2.45, a 4.3% increase. Operating margin improved to 10.4% from 8.2% year-on-year. Management indicated no plans for divestitures, focusing instead on current product mix and gradual market share recovery.

Yahoo Finance
May 5th, 2026
Integra LifeSciences beats Q1 guidance, raises EPS outlook on tariff gains

Integra LifeSciences reported first-quarter results exceeding guidance, with revenue of $392 million and adjusted earnings per share of $0.54. Revenue increased 2.4% on a reported basis and 1.3% organically, driven by product demand and supply improvements. The company announced leadership changes, with Chairman Stuart Essig resuming the role of President and CEO following Mojdeh Poul's departure. Essig said the decision was mutual and cited differences in strategic topics, though transformation initiatives will continue. Mike McBreen was appointed as the company's first Chief Commercial Officer to elevate commercial priorities. Integra raised its full-year adjusted EPS guidance by $0.10, primarily due to favourable tariff outcomes in the first quarter. CFO Lea Knight noted a $0.02 net tariff benefit but said future tariff assumptions remain uncertain.

Associated Press
May 5th, 2026
Integra LifeSciences Q1 revenues rise 2.4% to $391.9M, raises full-year EPS guidance

Integra LifeSciences reported first quarter 2026 revenues of $391.9 million, up 2.4% on a reported basis and 1.3% organically compared to the prior year. The medical technology company posted adjusted earnings per diluted share of $0.54, up from $0.41 in the prior year. The company reaffirmed full-year 2026 revenue guidance of $1.662 billion to $1.702 billion whilst raising its adjusted earnings per share guidance to $2.40 to $2.50, up from the previous range of $2.30 to $2.40. Adjusted EBITDA for the quarter was $76.2 million, representing 19.4% of revenue, compared to $63.6 million or 16.6% in the prior year. The company generated $9.8 million in operating cash flow during the quarter, with net debt standing at $1.6 billion.